David P. Walling, PhD
Collaborative Neuroscience Network Garden Grove, Garden Grove, California
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
Original Research
Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis
September 21, 2021
Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
Original Research
Asenapine Transdermal System for Schizophrenia
December 15, 2020
Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch),...
